A VC fund based in the U.S. invests in early-stage applied AI companies in healthcare, enterprise, and automation. The firm follows their thesis of partnering and investing in entrepreneurs who have a deep desire to use AI-enabled technology to tackle the most challenging problems in the given industries. The founder, a tech entrepreneur themself, started the fund with the idea of wanting to pay it forward towards startups that can make a large impact in the world. The firm can invest in Seed to Series B rounds with check size ranging from $250k-4M USD. The firm focuses on companies in the U.S., Canada, and the U.K. The firm can lead investments as they like to be active investors, utilizing their strong network to help companies with operations, funding, commercialization, and more.
In terms of healthcare, the firm invests in companies that blend technology toward healthcare applications; what the firm likes to call “tech-bio”. Some examples include technology that can improve how drugs are discovered, targeted and delivered, that drive clinical results with biased-free patient selection and data transparency, digital therapeutics, and precision medicine. The goal is to improve patient outcomes and serve multiple customers and pipelines. The firm is not interested in traditional assets.
The firm prefers to take a board seat however, it is not required.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment